Pharma BD Deal Intelligence
Nebula Genomics founded by Harvard geneticist George Church acquired by ProPhase Labs in 2021 for consumer whole genome sequencing services
ProPhase Labs acquires Nebula Genomics whole genome sequencing company to integrate with CLIA-certified molecular testing laboratories
ProPhase Labs acquires whole genome sequencing company Nebula Genomics for approximately $14.6 million in stock and cash combination
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
ProPhase Labs (Nasdaq: PRPH) acquired whole-genome-sequencing direct-to-consumer company Nebula Genomics, announced and closed August 11, 2021, for consideration of $7.3M cash plus $7.3M in ProPhase stock (Nebula became a wholly owned subsidiary). The acquisition added consumer whole-genome sequencing (later marketed as DNA Complete) to ProPhase's diagnostics/genomics push alongside its COVID-19 testing business. Post-close (FY2025), ProPhase restructured the asset: it shut its genomics laboratory in February 2025, ran a strategic-alternatives/sale process for Nebula, and deconsolidated the business -- recognizing a $43.491M 'Investment in unconsolidated affiliates' on the December 31, 2025 balance sheet (deconsolidation of ~$16.0M of subsidiary assets and liabilities). Management reported Nebula/DNA Complete operating profitably on a standalone basis at year-end 2025.
0 US cases/yr · $6.0B ~$6B consumer genomics market (2024)
Nebula Genomics offers affordable whole genome sequencing to consumers, providing 30x coverage compared to SNP-based genotyping from 23andMe and Ancestry. ProPhase Labs acquired Nebula to build a genomics diagnostics division alongside its legacy OTC healthcare business, gaining genomic data assets and bioinformatics capabilities.
Nebula differentiates from 23andMe and Ancestry by offering clinical-grade whole genome sequencing at consumer prices ($249-$999). The platform sequences 100% of DNA vs less than 0.1% for SNP arrays, enabling detection of rare variants, structural variants, and pharmacogenomic insights. ProPhase integrated Nebula with CLIA-certified lab operations.
ProPhase Labs recognized a $43.491M investment in unconsolidated affiliates at 12/31/2025 (deconsolidation of ~$16.0M subsidiary assets/liabilities) after shutting its genomics lab (Feb 2025) and running a Nebula sale/strategic-alternatives process; Nebula/DNA Complete reported profitable standalone.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| ProPhase Labs / Nebula Genomics (this deal) | 2021 | $15M | 48 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
| Jazz Pharmaceuticals PLC / GW Pharmaceuticals | 2021 | $7.2B | 77 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
← Browse all deals · How we score deals
More: 2021 deals